KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Notes Payables (2016 - 2025)

Historic Notes Payables for Novartis Ag (NVS) over the last 11 years, with Q4 2025 value amounting to $682.0 million.

  • Novartis Ag's Notes Payables rose 623.05% to $682.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $682.0 million, marking a year-over-year increase of 623.05%. This contributed to the annual value of $682.0 million for FY2025, which is 623.05% up from last year.
  • According to the latest figures from Q4 2025, Novartis Ag's Notes Payables is $682.0 million, which was up 623.05% from $642.0 million recorded in Q4 2024.
  • In the past 5 years, Novartis Ag's Notes Payables registered a high of $899.0 million during Q4 2021, and its lowest value of $624.0 million during Q4 2023.
  • Moreover, its 5-year median value for Notes Payables was $682.0 million (2025), whereas its average is $742.0 million.
  • As far as peak fluctuations go, Novartis Ag's Notes Payables tumbled by 2769.41% in 2023, and later soared by 623.05% in 2025.
  • Quarter analysis of 5 years shows Novartis Ag's Notes Payables stood at $899.0 million in 2021, then dropped by 4.0% to $863.0 million in 2022, then dropped by 27.69% to $624.0 million in 2023, then rose by 2.88% to $642.0 million in 2024, then grew by 6.23% to $682.0 million in 2025.
  • Its last three reported values are $682.0 million in Q4 2025, $642.0 million for Q4 2024, and $624.0 million during Q4 2023.